Vice President, Head of EMEA Medical Affairs
What’s in it for you?
The VP, Head of EMEA Medical Affairs, reporting to the SVP, Head of Medical Affairs, will be a member of the Global Medical Affairs Leadership Team, responsible for growing and leading the Medical Affairs team in the combined region of Europe, Middle-East and Africa. The successful candidate will lead the regional medical team, accountable for the development and execution of country medical plans in the EMEA region across all therapeutic areas in alignment with global medical plan. This individual will represent medical affairs at the regional management team, contributing to the development of regional strategy.
What will you be doing?
- Provide leadership and oversight of the country medical teams in the EMEA region; serve as a player-coach as required
- Partner with Global Medical Affairs Strategy team to ensure country medical plans are developed in alignment with global medical strategy
- Partner with key stakeholders to define operating principles to guide evidence-based medical affairs activities and ensure all activities are compliant with local laws and regulations
- Set performance metrics for country medical teams, ensuring effective execution of local medical plans in alignment with global medical strategy
- Partner with Global Medical Directors on post-approval evidence generation (e.g. phase 4, investigator-initiated studies, chart reviews) in the EMEA region, aligned with the global evidence generation strategy to address strategic data gaps (e.g. payer data needs)
- Partner with local/regional stakeholders both internally and externally to support reimbursement applications and patient access
- Represent medical affairs team at the EMEA Leadership Team and contribute to the development of regional strategy
- Provide medical expertise as needed to assist in the development and execution of compliant commercial activities
- Partner with global medical team and other R&D functions to provide medical affairs input on clinical trial design and support clinical trial enrollment
What are we looking for?
The successful candidate will possess the following capabilities and characteristics:
- MD, PhD in life sciences, or PharmD
- Ideally located in the Zug /Zurich area
- 15+ years of demonstrated high-level professional knowledge and skills in the areas of medical affairs and/or life sciences industry
- 7+ years of people management experience in the medical / clinical area (e.g. medical affairs, and/or clinical development) or similar settings
- Demonstrated reputation as a well-respected, dynamic team leader with strong leadership and people management skills
- Prior experience working in the pulmonary therapeutic area preferred but not required
- Strong written, verbal communication skills, and interpersonal skills
- Capable of managing shifting priorities in a rapidly changing and environment
- Travel will be required (approximately 25%)
How will you grow with us?
This role provides an exciting opportunity to be a key player in furthering the company’s goal of becoming a leader in the pulmonary space. As a rapidly growing company with multiple assets in development and key regulatory milestones on the horizon, you have an opportunity to leverage your expertise and help shape the growing Medical Affairs team. With one approved product, and an exciting pipeline, Acceleron is in a phase of dynamic growth with opportunities to make a positive impact on patients’ lives.
*In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and complete the required employment eligibility verification document form upon hire.
*Recruiters - please do not send unsolicited resumes to this posting.
FOR IMMEDIATE CONSIDERATION PLEASE SUBMIT YOUR RESUME TO:
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.